<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32563609</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>33</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.</ArticleTitle><Pagination><StartPage>5313</StartPage><EndPage>5323</EndPage><MedlinePgn>5313-5323</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2020.05.081</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(20)30736-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">To increase the global supply of affordable IPV vaccine, preferably using Sabin viruses to comply with GAPIII requirements, Takeda has assessed three dosages of a stand-alone sIPV.</AbstractText><AbstractText Label="METHODS">In this phase I/II study two cohorts of 40 adults and 60 toddlers, respectively, were initially assessed for safety after receiving high-dosage sIPV compared with placebo (adults) or Salk IPV (toddlers). A cohort of 240 infants was then enrolled and randomized (1:1:1:1) to receive low-, medium- or high-dosage sIPV, or a reference Salk IPV in a three-dose primary schedule at 6, 10 and 14&#xa0;weeks of age. Parents completed safety diaries for 4&#xa0;weeks after each dose, and immunogenicity was measured as neutralization antibody titers at baseline and four weeks after vaccination.</AbstractText><AbstractText Label="RESULTS">All vaccinations were generally well-tolerated and sIPV had a comparable safety profile to the control arm in adults or the reference Salk IPV vaccine in toddlers and infants. Infants displayed dosage-dependent immune responses to sIPV when assayed using Sabin strains, which were equivalent to the reference IPV in the high-dosage sIPV group for serotypes 1 and 2, but not for Sabin and Salk serotype 3. Seroconversion rates (SCR) of the low- and medium-dosage groups were significantly lower than the Salk IPV group for both Sabin and Salk serotypes 1 and type 2 (p&#xa0;&lt;&#xa0;0.05), with no significant differences for Salk or Sabin serotypes 3. Responses to sIPV, particularly to Sabin types 1 and 2, were higher in initially seronegative infants, indicating possible interference by maternally-derived antibodies.</AbstractText><AbstractText Label="CONCLUSIONS">A novel stand-alone Sabin-based IPV vaccine was well tolerated with an acceptable safety profile, but less immunogenic than reference Salk IPV at 6, 10 and 14&#xa0;weeks of age for Salk serotypes 1 and 2, with apparent interference by maternal antibodies. Additional preclinical assessments will be made before any further clinical development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Takeda Vaccines Inc. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Jakob P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimeno</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases at Hospital del Ni&#xf1;o Dr. Jos&#xe9; Ren&#xe1;n Esquivel, Sistema Nacional de Investigaci&#xf3;n at SENACYT, Centro de Vacunaci&#xf3;n Internacional (Cevaxin), Panama City, Panama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Htay Htay</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Takeda Vaccines, Inc., Cambridge, USA. Electronic address: htay-htay.han@takeda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Stella</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Takeda Vaccines, Inc., Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borkowski</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;ez-Llorens</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases at Hospital del Ni&#xf1;o Dr. Jos&#xe9; Ren&#xe1;n Esquivel, Sistema Nacional de Investigaci&#xf3;n at SENACYT, Centro de Vacunaci&#xf3;n Internacional (Cevaxin), Panama City, Panama, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inactivated vaccine</Keyword><Keyword MajorTopicYN="N">Infnats</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">Sabin</Keyword><Keyword MajorTopicYN="N">Toddlers</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32563609</ArticleId><ArticleId IdType="pmc">PMC7347011</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2020.05.081</ArticleId><ArticleId IdType="pii">S0264-410X(20)30736-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared. http://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared/ Accessed 20 March 2020.</Citation></Reference><Reference><Citation>WHO. Two out of three wild poliovirus strains eradicated: Global eradication of wild poliovirus type 3 declared on World Polio Day - 24 October 2019. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated Accessed 20 March 2020.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio this week as of 18 March 2020. http://polioeradication.org/polio-today/polio-now/this-week/ Accessed 20 March 2020.</Citation></Reference><Reference><Citation>WHO. What is vaccine-derived polio? https://www.who.int/features/qa/64/en/ Accessed 24 November 2019.</Citation></Reference><Reference><Citation>SAGE Polio Working Group Report. Proposed policy for a switch from tOPV to bOPV globally. April 10, 2012.</Citation></Reference><Reference><Citation>Okayasu H., Sutter R.W., Jafari H.S., Takane M., Aylward R.B. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(Suppl 1):S459&#x2013;S464.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316868</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO SAGE. GAPIII Containment Certification Scheme, October 2016. http://polioeradication.org/wp-content/uploads/2016/10/CCS.pdf Accessed 20 March 2020.</Citation></Reference><Reference><Citation>Okayasu H., Sein C., Hamidi A., Bakker W.A.M., Sutter R.W. Development of inactivated poliovirus vaccine from Sabin strains: A progress report. Biologicals. 2016;44:581&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker WA, Thomassen YE, Van&#x2019;t Oever AG, Westdijk J, van Oijen MG, Sundermann LC, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011;29:7188&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651934</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdijk P., Rots N.Y., van Oijen M.G., Oberste M.S., Boog C.J., Okayasu H. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminium hydroxide: A phase 1 trial in healthy adults. Vaccine. 2013;31:5531&#x2013;5536.</Citation><ArticleIdList><ArticleId IdType="pubmed">24063976</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S., Tejeda A., Fonseca M., Alema&#xf1;i N., Diaz M., Martinez Y. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba. Vaccine. 2014;32(42):5399&#x2013;5404.</Citation><ArticleIdList><ArticleId IdType="pubmed">25131734</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K., Ying Z., Wang L., Hu Y., Xia J., Chen L. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine. 2018;29:6782&#x2013;6789.</Citation><ArticleIdList><ArticleId IdType="pubmed">30249424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G., Li R., Li C., Sun M., Li Y., Chu J. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158682</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G., Li R., Li C., Sun M., Jiang S., Li Y. Phase 3 trial of a Sabin strain-based inactivated poliovirus vaccine. J Infect Dis. 2016;214(11):1728&#x2013;1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdijk P., Rots N.Y., van Oijen M.G. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 2014;32(39):4938&#x2013;4944.</Citation><ArticleIdList><ArticleId IdType="pubmed">25043278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano T., Sumino S., Takanami Y., Mitsuya N., Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother. 2018;14(12):2940&#x2013;2949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343622</ArticleId><ArticleId IdType="pubmed">30047808</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., Okayasu H., Kieny M.-P. Next generation inactivated poliovirus vaccine: the future has arrived. Clin Infect Dis. 2017;64(10):1326&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">28200099</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K., Miyazaki C., Kino Y., Ozaki T., Hirose M., Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV) J Infect Dis. 2013;208(2):275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">23568174</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). Replacement of Annex 2 of WHO Technical Report Series, No. 910. Available at: https://www.who.int/biologicals/vaccines/Annex3_IPV_Recommendations_eng.pdf?ua=1 Accessed 20 March 2020.</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. 2016. Standardized methods for detection of poliovirus antibodies. In: Methods in Molecular Biology; Martin J, ed. Humana Press, New York; vol. 1378, pp 145&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17(8):873&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">9595617</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias E.J., Bandyopadhyay A.S., Self S., Rivera L., Saez-Llorens X., Lopez E. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants. Lancet. 2016;388(10040):158&#x2013;169. doi: 10.1016/S0140-6736(16)00703-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00703-0</ArticleId><ArticleId IdType="pubmed">27212429</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez-Llorens X., Clemens R., Leroux-Roels G., Jimeno J., Clemens S.A. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16(3):321&#x2013;330. doi: 10.1016/S1473-3099(15)00488-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)00488-0</ArticleId><ArticleId IdType="pmc">PMC9108810</ArticleId><ArticleId IdType="pubmed">26719058</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins F.T., Yetts R. poliomyelitis immunization in infants in the presence of maternally transmitted antibody. Br Med J. 1961;1(5223):404&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1953311</ArticleId><ArticleId IdType="pubmed">13734397</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder N., Handsher R., German B., Sirota L., Bachman M., Zinger S. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed. 2000;83(1):F24&#x2013;F27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1721105</ArticleId><ArticleId IdType="pubmed">10873167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormunen H., Stenvik M., Eskola J., Hovi T. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol. 2001;63(4):305&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11241462</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias E.J., Dueger E.L., Omer S.B., Melville A., Nates S.V., Laassri M. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis. 2007;196(5):692&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">17674310</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan G.H., Thorley M., Yamamura Y., Rodr&#xed;guez N., McLaughlin S., Torres L.M. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis. 2007;195(1):12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17152004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaensbauer J.T., Gast C., Bandyopadhyay A.S., O'Ryan M., Saez-Llorens X., Rivera L. Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame. Clin Infect Dis. 2018;67(Suppl 1):S57&#x2013;S65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206111</ArticleId><ArticleId IdType="pubmed">30376095</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang R., Chu K., Hu Y., Chen L., Zhang M., Liu S. Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains. Hum Vaccin Immunother. 2019:1&#x2013;7. doi: 10.1080/21645515.2019.1572410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1572410</ArticleId><ArticleId IdType="pmc">PMC6605855</ArticleId><ArticleId IdType="pubmed">30676838</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A guide to introducing inactivated polio vaccine: Based on the Polio Eradication &amp; Endgame Strategic Plan 2013-2018. 2016. Available at: https://www.who.int/immunization/diseases/poliomyelitis/endgame_objective2/inactivated_polio_vaccine/Introduction_guide.pdf?ua=1 Accessed 20 March 2020.</Citation></Reference><Reference><Citation>Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201(9):1344&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">20350164</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh H., Tanaka-Taya K., Shimizu H., Goto A., Tanaka S., Nakano T. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Vaccine. 2019;37(14):1964&#x2013;1971. doi: 10.1016/j.vaccine.2019.02.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.02.034</ArticleId><ArticleId IdType="pubmed">30827736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M., Li C., Xu W., Liao G., Li R., Zhou J. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">28419204</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawt L., Atkinson E., Tedcastle A., Pegg E., Minor P., Cooper G. Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays. J Infect Dis. 2020;221(4):544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">30788503</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>